Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearance.

about

Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis.

P2860

Q47688442-152AE8F4-08D2-4349-AC49-F94174F856BB

P2860

Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearance.

Item

http://www.wikidata.org/entity/Q41841260

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Predictive value of the effica ...... ts using free water clearance.

@en

type

Item

label

Predictive value of the effica ...... ts using free water clearance.

@en

prefLabel

Predictive value of the effica ...... ts using free water clearance.

@en

P1476

Predictive value of the effica ...... ts using free water clearance.

@en

P2093

Hidetaka Shibata

http://www.w3.org/2001/XMLSchema#string

Hisamitsu Miyaaki

http://www.w3.org/2001/XMLSchema#string

Kazuhiko Nakao

http://www.w3.org/2001/XMLSchema#string

Naota Taura

http://www.w3.org/2001/XMLSchema#string

Satoshi Miuma

http://www.w3.org/2001/XMLSchema#string

Takuya Honda

http://www.w3.org/2001/XMLSchema#string

Tatsuki Ichikawa

http://www.w3.org/2001/XMLSchema#string

Yutaka Nakamura

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats

The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club.

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.

Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients

Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan

Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial.

Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis.

Correlation between changes in bodyweight and changes in ascites volume in liver cirrhosis patients with hepatic edema in short-term diuretic therapy.

P304

884-886

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/BR.2015.521

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26623035

http://www.w3.org/2001/XMLSchema#string

P932

4660650

http://www.w3.org/2001/XMLSchema#string

Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearance.

about

P2860

P2860

Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearance.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932